Wei Lu
Vice President - Research OnCusp Therapeutics
Seminars
Thursday 21st August 2025
CUSP06, a CDH6-targeting ADC Utixlizing a Novel T1000-Exatecan Platform Demonstrates Promising Antitumor Activities
10:00 am
- T1000-exatecan is a novel platform with desired stability and safety profile and overcome drug-resistance mechanism
- CUSP06 demonstrates target-dependent cell killing and antitumor activities in vitro and in vivo
- Clean safety profile of CUSP06 from GLP toxicology studies indicates the excellent stability of T1000-exatecan
